Mutation spectrum and genotype-phenotype correlations in a large french cohort of myh9-related disorders

Molecular Genetics and Genomic Medicine

Volumn 2, Issue 4, 2014, Pages 297-312

  Saposnik, Beatrice ^a   Binard, Sylvie ^a   Fenneteau, Odile ^a   Nurden, Alan ^b   Nurden, Paquita ^b   Hurtaud Roux, Marie Francoise ^a   Schlegel, Nicole ^a  

^a HÔPITAL ROBERT DEBRÉ   (France)

^b Ctr Geriatrie Ctr Hosp Univ B   (France)

Author keywords

Inherited platelet disorders; Leukocyte inclusions; Macrothrombocytopenia; Mutation analysis; MYH9 RD

Indexed keywords

EID: 84904761683     PISSN: None     EISSN: 23249269     Source Type: Journal    
DOI: 10.1002/mgg3.68     Document Type: Article

References (37)

1. Althaus, K., and A. Greinacher. 2009. MYH9-Related platelet disorders. Semin. Thromb. Haemost. 35:189–203.
2. Balduini, C. L., A. Iolascon, and A. Savoia. 2002. Inherited thrombocytopenias: from genes to therapy. Haematologica 87:860–880.
3. Balduini, C. L., A. Pecci, and A. Savoia. 2011. Recent advances in the understanding and management of MYH9-related inherited thrombocytopenias. Br. J. Haematol. 154:161–174.
4. Balduini, C. L., A. Pecci, and P. Noris. 2012. Inherited thrombocytopenias: the evolving spectrum. Hamostaseologie 32:259–270.
5. Balduini, C. L., A. Savoia, and M. Seri. 2013. Inherited thrombocytopenias frequently diagnosed in adults. J. Thromb. Haemost. 11:1006–1019.
6. Capria, M., M. Andreucci, L. Fuiano, D. Mancuso, P. Cianfrone, N. Comi, et al. 2004. Double nucleotidic mutation of the MYH9 gene in a young patient with end-stage renal disease. Nephrol. Dial. Transplant. 19:249–251.
7. Chen, Y., S. Boukour, R. Milloud, R. Favier, B. Saposnik, and N. Schlegel, et al. 2013. The abnormal proplatelet formation in MYH9-related macrothrombocytopenia results from an increased actomyosin contractility and is rescued by myosin IIA inhibition. J. Thromb. Haemost. 11:2163–2165.
8. De Rocco, D., B. Zieger, H. Platokouki, P. G. Heller, A. Pastore, R. Bottega, et al. 2013. MYH9-related disease: five novel mutations expanding the spectrum of causative mutations and confirming genotype/phenotype correlations. Eur. J. Med. Genet. 56:7–12.
9. Dong, F., S. Li, N. Pujol-Moix, N. L. C. Luban, S. Won Shin, J. H. Seo, et al. 2005. Genotype-phenotype correlation in MYH9-related thrombocytopenia. Br. J. Haematol. 130:620–627.
10. Franke, J. D., F. Dong, W. L. Rickoll, M. J. Kelley, and D. P. Kiehart. 2005. Rod mutations associated with MYH9-related disorders disrupt nonmuscle myosin-IIA assembly. Blood 105:161–169.
11. Glembotsky, A. C., R. F. Marta, A. Pecci, D. De Rocco, C. Gnan, Y. R. Espasandin, et al. 2012. International collaboration as a tool for diagnosis of patients with inherited thrombocytopenia in the setting of a developing country. J. Thromb. Haemost. 10:1653–1661.
12. Heath, K. E., A. Campos-Barros, A. Toren, G. Rozenfeld-Granot, L. E. Carlsson, J. Savige, et al. 2001. Nonmuscle myosin heavy chain IIA mutations define a spectrum of autosomal dominant macrothrombocytopenias: May-Hegglin anomaly and Fechtner, Sebastian, Epstein, and Alport-like syndromes. Am. J. Hum. Genet. 69:1033–1045.
13. Hildebrand, M. S., M. G. de Silva, R. J. Gardner, E. Rose, C. A. de Graaf, M. Bahlo, et al. 2006. Cochlear implants for DFNA17 deafness. Laryngoscope 116:2211–2215.
14. Ishida, M., Y. Mori, N. Ota, T. Inaba, and S. Kunishima. 2012. Association of a novel in-frame deletion mutation of the MYH9 gene with end-stage renal failure: case report and review of the literature. Clin. Nephrol. 80:218–222.
15. Jang, M. J., H. J. Park, S. Y. Chong, J. Y. Huh, I. H. Kim, J. H. Jang, et al. 2012. Trp33Arg mutation at exon 1 of the MYH9 gene in a Korean patient with May-Hegglin anomaly. Yonsei Med. J. 53:662–666.
16. Kunishima, S., T. Matsushita, T. Kojima, N. Amemiya, Y. M. Choi, N. Hosaka, et al. 2001. Identification of six novel MYH9 mutations and genotype-phenotype relationships in autosomal dominant macrothrombocytopenia with leukocyte inclusions. J. Hum. Genet. 46:722–729.
17. Kunishima, S., T. Matsushita, T. Kojima, M. Sako, F. Kimura, E. K. Jo, et al. 2003. Immunofluorescence analysis of neutrophil nonmuscle myosin heavy chain-A in MYH 9 disorders: association of subcellular localization with MYH9 mutations. Lab. Invest. 83:115–122.
18. Kunishima, S., T. Matsushita, T. Yoshihara, Y. Nakase, K. Yokoi, M. Hamaguchi, et al. 2005. First description of somatic mosaicism in MYH9 disorders. Br. J. Haematol. 128:360–365.
19. Kunishima, S., M. Yoshinari, H. Nishio, K. Ida, T. Miura, T. Matsushita, et al. 2007. Haematological characteristics of MYH9 disorders due to MYH9 R702 mutations. Eur. J. Haematol. 78:220–226.
20. Kunishima, S., T. Matsushita, M. Hamaguchi, and H. Saito. 2008. Identification and characterization of the first large deletion of the MYH9 gene associated with MYH9 disorders. Eur. J. Haematol. 80:540–544.
21. Kunishima, S., K. Takaki, Y. Ito, and H. Saito. 2009. Germinal mosaicism in MYH9 disorders: a family with two affected siblings of normal parents. Br. J. Haematol. 145:260–262.
22. Kunishima, S., T. Tomii, K. Kudo, H. Saito, 2012. G to T transversion at the first nucleotide of exon 26 of the MYH9 gene results in a novel missense mutation and abnormal splicing in platelets: comment on “A G to C transversion at the last nucleotide of exon 25 of the MYH9 gene results in a missense mutation rather than in a splicing defecton” by Vettore, et al. Eur. J. Med. Genet. 55:763–765.
23. Lalwani, A. K., J. A. Goldstein, M. J. Kelley, W. Luxford, C. M. Castelein, and A. N. Mhatre. 2000. Human nonsyndromic hereditary deafness DFNA17 is due to a mutation in nonmuscle myosin MYH9. Am. J. Hum. Genet. 67:1121–1128.
24. Latger-Cannard, V., M. Hoarau, S. Salignac, D. Baumgart, P. Nurden, and T. Lecompte. 2012. Mean platelet volume: comparison of three analysers towards standardization of platelet morphological phenotype. Int. J. Lab. Hematol. 34:300–310.
25. Latger-Cannard, V., O. Fenneteau, S. Salignac, T. P. Lecompte, and N. Schlegel. 2013. Platelet morphology analysis. Pp. 207–225 in P. Monagle, ed. Haemostasis: methods and protocols, methods in molecular biology, Vol. 992. Springer, New York, NY.
26. Miyajima, Y., and S. Kunishima. 2009. Identification of the first in cis mutations in MYH9 disorder. Eur. J. Haematol. 82:288–291.
27. Noris, P., C. Klersy, M. Zecca, L. Arcaini, A. Pecci, F. Melazzini, et al. 2009. Platelet size distinguishes between inherited macrothrombocytopenias and immune thrombocytopenia. J. Thromb. Haemost. 7:2131–2136.
28. Noris, P., C. Klersy, P. Gresele, F. Giona, P. Giordano, P. Minuz, et al. 2013. Platelet size for distinguishing between inherited thrombocytopenias and immune thrombocytopenia: a multicentric, real life study. Br. J. Haematol. 162:112–119.
29. Pecci, A., E. Panza, N. Pujol-Moix, C. Klersy, F. Di Bari, V. Bozzi, et al. 2008. Position of nonmuscle myosin heavy chain IIA (NMMHC-IIA) mutations predicts the natural history of MH9-related disease. Hum. Mutat. 29:409–417.
30. Pertuy, F., A. Eckly, J. Weber, F. Proamer, J. Y. Rinckel, and F. Lanza, et al. 2013. Myosin IIA is critical for organelle distribution and F-actin organization in megakaryocytes and platelets. Blood. doi: 10.1182/blood-2013-06-508168
31. Saito, H., and S. Kunishima. 2009. May-Hegglin Anomaly: morphologic and clinical manifestations. Clin. Adv. Hematol. Oncol. 7:111–113.
32. Savoia, A., D. De Rocco, E. Panza, V. Bozzi, R. Scandellari, G. Loffredo, et al. 2010. Heavy chain myosin 9-related disease (MYH9-RD): neutrophil inclusions of myosin-9 as a pathognomonic sign of the disorder. Thromb. Haemost. 103:826–832.
33. Sellers, J. R. 2000. Myosins: a diverse superfamily. Biochim. Biophys. Acta 1496:3–22.
34. Seri, M., R. Cusano, S. Gangarossa, G. Caridi, D. Bordo, C. Lo Nigro, et al. 2000. Mutations in MYH9 result in the May-Hegglin anomaly, and Fechtner and Sebastian syndromes. The May-Hegglin/Fechtner Syndrome Consortium. Nat. Genet. 26:103–105.
35. Seri, M., A. Pecci, F. Di Bari, R. Cusano, M. Savino, E. Panza, et al. 2003. MYH9-related disease: May-Hegglin anomaly, Sebastian syndrome, Fechtner syndrome, and Epstein syndrome are not distinct entities but represent a variable expression of a single illness. Medicine (Baltimore) 82:203– 215.
36. Slichter, S. J. 2007. Evidence-based platelet transfusion guidelines. Hematology Am. Soc. Hematol. Educ. Progam, 172–178.
37. Sun, X. H., Z. Y. Wang, H. Y. Yang, L. J. Cao, J. Su, and Z. Q. Yu, et al. 2013. Clinical, pathological and genetic analysis of ten patients with MYH9-related disease. Acta Haematol. 129:106–113.